कंपनी का अवलोकन
Organogenesis Holdings Inc. operates within the healthcare sector, specifically functioning in the drug manufacturers - specialty & generic industry, where it develops, manufactures, and commercializes products for the advanced wound care, surgical, and sports medicine markets in the United States. The company's primary focus lies in regenerative medicine, offering specialized solutions such as Affinity and Novachor, which utilize amnion and chorion for therapeutic applications. This entity maintains a significant operational footprint with a workforce of 854 employees, reflecting its established presence in a high-barrier-to-entry industry. The company currently holds a market capitalization of $307.45M and generates annual revenue of $564.17M, indicating a mid-cap status that suggests it has moved beyond the initial startup phase while still operating with a valuation typical of specialized pharmaceutical firms rather than large-cap blue-chip companies.
वित्तीय स्वास्थ्य
Organogenesis Holdings Inc. reported a trailing twelve-month revenue of $564.17M and a net income of $20.02M, resulting in an EBITDA of $74.98M, which highlights a substantial gap between top-line earnings and bottom-line profit that points to significant operating expenses or non-operating costs affecting the final profitability. The company's free cash flow stands at -$50,102,376, a figure that indicates a current lack of financial flexibility and suggests the organization is utilizing its cash reserves to fund capital expenditures or expansion initiatives rather than generating excess cash flow from operations. In terms of profitability efficiency, the gross margin is 75.6%, the operating margin is 28.9%, and the profit margin is 6.6%, showing that while production costs are well-controlled, the final profit margin is compressed, likely due to high research, development, or sales expenses inherent in the specialty drug manufacturing sector. The firm holds $95.92M in cash against $82.14M in debt, creating a net cash position, and maintains a debt-to-equity ratio of 18.93%, which represents a low level of leverage for a manufacturing company. Additionally, the current ratio of 3.62 demonstrates robust short-term liquidity, ensuring the company can easily meet its current liabilities with its available current assets. Finally, the return on equity is 9.0% and the return on assets is 6.4%, metrics that reveal moderate management effectiveness in generating profits from shareholders' equity and the total asset base, respectively.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is 15.93, while the forward P/E is significantly lower at 8.24, implying that the market expects earnings to grow substantially in the coming year, thereby lowering the multiple required to value the stock. The price-to-book ratio of 1.01 suggests that the stock is trading at approximately par value, indicating no significant market premium or discount over the company's net asset value. Alternative valuation metrics such as the price-to-sales ratio of 0.54 and an EV/EBITDA of 5.70 further suggest that the stock is priced conservatively relative to its sales and earnings power, often seen in growth-oriented biotechnology or pharmaceutical companies. The 52-week price range spans from a low of $2.21 to a high of $7.08, providing a clear context for recent price volatility and trading bands. Regarding the current price position relative to the 52-week high and low, without a specific current price provided in the facts, the metrics define the total trading range over the past year, which is crucial for understanding historical volatility. The beta of 1.48 indicates that the stock's price volatility is 48% higher than the broader market, signifying that the share price is expected to move more aggressively than the S&P 500 during periods of market turbulence.
Growth & Income
The company has achieved impressive expansion with revenue growth of 78.1% year-over-year and earnings growth of 555.2% year-over-year, demonstrating that earnings are growing at a rate significantly faster than revenue, which often implies improving operational leverage or one-time gains influencing the bottom line. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning that all net income is retained within the business to fund research, development, and commercialization efforts rather than being distributed to shareholders. The absence of a dividend policy aligns with the growth profile of a regenerative medicine company reinvesting capital to capture market share and advance its product pipeline. Overall, the growth and income profile is characterized by exceptional earnings acceleration and zero dividend distribution, positioning the firm as a pure growth investment within the healthcare sector.